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In a population-based, retrospective cohort study of 16541 3-year survivors of childhood cancer treated in Britain up to the end of
1987, 278 second malignant neoplasms (SMNs) were identified against 39.4 expected giving a standardised incidence ratio (SIR) of
6.2. The overall cumulative risk of an SMN by 25 years from 3-year survival from childhood cancer was 4.2%. Analysis of the cohort of
nonretinoblastoma childhood cancers combined revealed a significant decline in SIR of SMN with increasing duration of follow-up.
There was a greater risk of developing a SMN, particularly secondary acute myeloid leukaemia, in those diagnosed with childhood
cancer from 1980 onwards. However, on multivariate modeling, this was not an independent risk factor. There was significant
heterogeneity (Po0.001) in SIR of SMN across different treatment groups, the greatest risk observed in the group exposed to both
radiotherapy and chemotherapy. The risks of SMN observed were comparable with those in other population-based studies. While
the decline in SIR with duration of follow-up and the small excess numbers of cancers observed over later decades after diagnosis are
reassuring, the high excess risk, particularly of leukaemia, associated with recent more intense therapy is of concern.
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Survival after childhood cancer has greatly improved over the last
three decades and most recent figures indicate that over 70% of
children with cancer are likely to survive at least 5 years (National
Registry of Childhood Tumours, unpublished). This growing popula-
tion of survivors, estimated at 1 in every 1000 young adults (Hawkins
and Stevens, 1996), is at risk of certain adverse late effects of both the
cancer and its treatment including second malignant neoplasms
(SMN). This long recognised increased risk (Meadows et al,1 9 8 5 )
represents perhaps the greatest challenge to long-term survival
(Robison and Mertens, 1993). Of multifactorial aetiology, risk has
been associated with the primary malignancy, exposure to che-
motherapy and radiotherapy and genetic predisposition (Kony et al,
1997). A major difficulty in the analysis of SMNs is the assembling of
large numbers of survivors who have been followed up over
sufficiently long periods of time with a wide spectrum of treatments.
We have investigated the risks of SMNs after childhood cancer
using a large UK population-based cohort of patients with substantially
longer average follow-up than that in previous comparable studies.
MATERIALS AND METHODS
Case ascertainment
The cohort was selected from the National Register of Childhood
Tumours (NRCT), a population-based national register covering
the whole of Great Britain, which is maintained by the Childhood
Cancer Research Group (CCRG) at the University of Oxford. The
registry is notified of all cancers occurring in individuals aged less
than 15 years through the national cancer registration system in
Britain, which was established in 1962. In addition, a complemen-
tary series of 3-year survivors of childhood cancer diagnosed prior
to this date was constructed from case lists from hospitals and
tumour registries that were known to be complete.
SMNs were ascertained by several methods in order to obtain the
most accurate estimation of the risk. Firstly, members of the cohort
were ‘flagged’ at the National Health Service Central Registers
(NHSCR), which provides automatic notification of the registration
of death or cancer in these individuals (Hawkins and Swerdlow,
1992). At the time of finalising the cohort, virtually all cancer
registrations up to 1990 had been processed at NHSCR and notified
to researchers. Secondly, a series of postal questionnaires about
SMNs were sent to the family doctors of childhood cancer survivors
over the period from 1982 to 1990; these provided an independent
source of ascertainment for 82% of the person-years of follow-up.
Finally, the CCRG receive all death certificates that mention neoplasia
in patients aged less than 20 years in Britain. These are routinely
checked, through family doctor and hospital notes, to identify cases
of multiple primary tumours. Cases were selected for the cohort if
they had been diagnosed with a malignant neoplasm before 1st
January 1988, aged less than 15 years at diagnosis and subsequently
survived at least 3 years. SMNs were included if they were diagnosed
before the end point of the study on 31st December 1990.
Pathological criteria
For each individual in the cohort, the first primary tumour (FPT)
was classified according to the International Classification of
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and subsequently categorised by the diagnostic group (Birch and
Marsden, 1987). SMNs were classified according to ICDO (World
Health Organization, 1976). In addition, all SMNs were classified
according to the International Classification of Diseases Ninth
Revision (World Health Organization, 1979), as national incidence
figures for this tumour classification are available for the general
population, stratified by sex, calendar year and 5-year age groups,
allowing statistical comparison. In all cases of a suspected SMN,
pathological material from the first and second cancers was
reviewed, if available, by a central pathologist (HBM).
Statistical methods
Statistical tests and confidence intervals were based on the
assumption that the observed numbers of cancers followed a Poisson
distribution with a mean equal to the expected number of cases.
Person-years at risk were accumulated from entry into the study (at
3-year survivorship) to exit from risk (first occurrence of SMN, died,
emigrated or reached 31/12/90). The expected numbers of cancers
were estimated by multiplying person-years at risk within specific
categories defined by age (5-year groups), sex and single calendar
year (from 1971) by the corresponding cancer incidence rate in the
general population (Breslow and Day, 1987; Office of National
Statistics, 1999). Standardised incidence ratios (SIR), the ratio of
observed to expected number of cancers, and the additive excess risk
(AER) were calculated. The AER is based on the difference between
the observed and expected number of SMNs and is a measure of the
excess number of cancers per 1000 survivors per year (Breslow and
Day, 1987). Nonmelanomatous skin cancer (ICD 8 and 9: 1730–
1739) was excluded from analysis, as being under-reported to cancer
registries, their inclusion would create bias. Statistical tests of
heterogeneity and trend in SIR were undertaken using standard
methods described by Breslow and Day (1987). The cumulative risk
was calculated using standard lifetable methods (Collett, 2003).
Multivariate Poisson regression models were used which
simultaneously accounted for the effect of treatment (neither
radiotherapy (RT) nor chemotherapy (CT)/RT alone/CT alone/
both RT and CT), era of first cancer diagnosis (pre-1970/1970–
1979/1980–1987), age at first cancer diagnosis (0–4/5–9/10–14
years) and length of follow-up on SMN risk (3–9/10–19/20–29/30
years or more) (Breslow and Day, 1987). Results are reported for all
SMNs combined (excluding skin), as the models failed to converge
for every specific type of SMN reported in Tables 4 and 5.
RESULTS
In all, 16541 cases of childhood cancer fulfilled the criteria for
inclusion in the overall cohort showing a male to female ratio of
1.2. The FPT were diagnosed between 1926 and 1987 with a mean
age at diagnosis of 6 years and 8 months (median; 5 years and 10
months). In total, 165879 person-years of follow-up were
accumulated during the study period, a mean follow-up per case
of 10 years. Of the 16541 3-year survivors in the cohort, 12932
(78%) were followed up to the end point of the study. A total of
3331 (20%) survivors were censored before the end point (210
emigrated and 3121 died), and 278 (2%) developed an SMN.
The relative frequencies of first primary childhood cancers
among individuals who developed an SMN were: central nervous
system tumours (24.5%), retinoblastoma (15.8%), Hodgkin’s
disease (12.9%), Wilm’s tumour (8.3%) and acute lymphoblastic
leukaemia (7.2%). Within the entire cohort of 3-year survivors, 278
SMNs (with ICD9 codes 1400-2089) were observed, of which 33
were nonmelanomatous skin cancers, leaving 245 cases for
analysis, compared to 39.4 expected, giving a SIR of 6.2 (95% CI:
5.5, 7.1). Table 1 reports the SIR associated with specific types of
SMN. The cumulative risk of developing an SMN within 20 years of
3-year survival from the first cancer was 3.1% (s.e.¼0.2%) and
within 25 years was 4.2% (s.e.¼0.3%). The overall AER was 1.2
extra cancers per 1000 survivors per year.
As the markedly increased risk of SMN following heritable
retinoblastoma is well established, this group was excluded, and
will be the subject of a separate report. Furthermore, in view of
uncertainty about the completeness of ascertainment of family
pedigree information in cases recorded as nonheritable retino-
blastoma, we have excluded all cases of retinoblastoma as FPT
(total 1089) from subsequent analyses.
Nonretinoblastoma childhood cancers
In all, 15452 cases were included in this cohort, with 147163
person-years of observation accrued, a mean follow-up of 9 years
and 6 months and a median follow-up of 7 years and 2 months.
Table 2 gives the overall SIR for any SMN and the SIRs for specific
sites of SMN. A total of 201 SMNs occurred during the study
period (excluding nonmelanomatous skin cancers) against 34.7
expected giving a SIR of 5.8 (95% CI: 5.0, 6.7). Among specific sites
of SMNs, the highest SIR was for bone cancer (SIR¼25.2) followed
by soft tissue (SIR¼15.9), endocrine (SIR¼13.9) and brain and
CNS (SIR¼13.4) sites. The cumulative risk of developing an SMN
within 20 years of 3-year survival was 2.8% (s.e.¼0.24%).
By duration of follow-up
Variation in risk of SMN with time from diagnosis was examined
in the following periods: 3–9, 10–19, 20–29 and 30 years or more
Table 1 Risk of developing an SMN and selected sites in 3-year survivors
of childhood cancer
Whole cohort (n¼16541)
SMN sites and ICD9 codes O SIR 95% CI for SIR
All (exc skin) 1400–2089 (exc 1730–1739) 245 6.2 5.5, 7.1
Digestive 1400–1599 32 9.1 6.2, 12.8
Respiratory 1600–1659 7 4.6 1.9, 9.5
Bone 1700–1709 60 41.1 31, 53.5
Soft tissue 1710–1719 17 16.1 9.4, 25.8
Breast (female) 1740–1749 14 3.1 1.7, 5.1
Brain/CNS 1910–1929 44 12.4 9, 16.6
Endocrine 1930–1949 14 13.4 7.3, 22.5
Leukaemia 2040–2089 23 5.8 3.6, 8.6
SMN¼second malignant neoplasm; O¼observed; SIR¼standardised incidence
ratio; CI¼confidence intervals; CNS¼central nervous system.
Table 2 Risk of developing an SMN and selected sites in 3-year survivors
of nonretinoblastoma childhood cancer
Nonretinoblastoma cohort (n¼15452)
SMN sites and ICD9 codes O SIR 95% CI for SIR
All (exc skin) 1400–2089
(exc 1730–1739)
201 5.8 5.0, 6.7
Digestive 1400–1599 27 8.8 5.8, 12.9
Respiratory 1600–1659 6 4.8 1.7, 10.3
Bone 1700–1709 33 25.2 17.3, 35.4
Soft tissue 1710–1719 15 15.9 8.9, 26.2
Breast (female) 1740–1749 11 2.8 1.4, 5.0
Brain/CNS 1910–1929 42 13.4 9.6, 18.1
Endocrine 1930–1949 13 13.9 7.4, 23.8
Leukaemia 2040–2089 23 6.5 4.2, 9.8
SMN¼second malignant neoplasm; O¼observed; SIR¼standardised incidence
ratio; CI¼confidence intervals; CNS¼central nervous system.
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risk interval, the observed and expected number of SMNs
occurring and the SIR and AER for each of these follow-up groups
are given in Table 3.
Univariate analysis demonstrated a statistically significant
decline (Po0.001) in the SIR over successive decades from
diagnosis (Table 3), persisting after adjusting for possible
confounding (P¼0.002) in a multivariate model also including
treatment, era of diagnosis and age at diagnosis of the first cancer.
There was a statistically significant excess SIR within each decade
of follow-up, the excess number of cancers remaining between one
and two extra cases per 1000 survivors per year over all follow-up
intervals.
SMNs at three sites demonstrated a statistically significant trend
in SIR with duration of follow-up: brain and central nervous system,
female breast and myeloid leukaemia (Table 4). The risk of myeloid
leukaemia was greatest within the first decade from diagnosis and
the later decline in risk was quite striking, with SIRs of 28.9, 2 and 4,
respectively, over the first three decades of follow-up.
By treatment of first cancer
Survivors were classified into four treatment categories: neither RT
nor CT, RT only, CT only and both RT and CT. There was evidence
of heterogeneity among the SIRs for any SMN (Po0.001), with the
greatest excess risk in cases receiving both RT and CT (SIR 12.5,
95% CI: 9.8, 15.8). This evidence of significant heterogeneity
persisted on multivariate analysis, which adjusted for the effect of
the other factors on treatment (Table 5). Among SIRs for SMNs at
selected sites, there was significant heterogeneity for secondary
leukaemia (Po0.001), in particular myeloid leukaemia (Po0.001)
(Table 5).
The SIR associated with treatment was initially calculated only
for the 82% of nonretinoblastoma cases in which treatment
information was available. However, since the treatment records of
patients with SMN were sought with much more effort than for
those not developing an SMN, such an analysis may be biased. The
SIR analysis was therefore repeated including the ‘no record’ cases
and assuming that all those for whom treatment details were not
available received the treatment being analysed, but the results
were not substantially different to those reported above (data not
shown).
By era and age at first cancer diagnosis
The risk of SMN was calculated for three main periods of diagnosis
of the first cancer: pre-1970, 1970–1979 and 1980 and later. The
SIR for all SMNs and specifically of the digestive tract and female
breast demonstrated a significant trend of increasing excess risk
with the more recent era of diagnosis (Table 5), particularly for
secondary myeloid leukaemia: (Po0.001) across the diagnostic
periods pre-1970, 1970–1979 and 1980 onwards, for which the
SIRs were 2.7, 11.4 and 69.9, respectively. However, when the SIR
for all SMNs was adjusted for other risk factors, the significant
trend seen on univariate analysis did not reach formal statistical
significance (P¼0.093).
Table 5 shows risk of SMN by age at diagnosis of the first cancer.
The SIR for SMN overall was greater with the first cancer under the
age of 5 years, a significant trend being observed in the SIR on
univariate analysis, which remained after adjustment for the effect
of the other factors detailed in the Statistical methods section
(P¼0.031).
Risk of SMN after selected types of first cancer
The SIRs of developing an SMN and the cumulative risks of
developing an SMN within 20 years of 3-year survivorship of
specific first cancer diagnoses are displayed in Table 6. The
cumulative risks are provided for only those specific types of first
cancer for which the mean period of follow-up exceeded 10 years.
DISCUSSION
After all childhood cancers combined
Our analysis of the long-term risks of SMN in a large, population-
based national cohort of 3-year survivors of childhood cancer
diagnosed between 1926 and 1987 develops previous work
covering part of this cohort followed-up until the end of 1981
(Hawkins et al, 1987); an additional 8 years of such survivors (over
6000) have now been added, more than doubling the total period of
person-years of follow-up. The mean period of follow-up of 10
years is substantially greater than other previously studied
population-based cohorts. Large population-based Nordic studies
of SMNs covered mean durations of follow-up of 6 years (Olsen
et al, 1993) and 7.5 years (Garwicz et al, 2000). Continued follow-
up provides an opportunity to assess long-term trends in risk and
helps clarify uncertainty, which still exists for long-term survivors.
In our overall cohort (including retinoblastomas), 278 SMNs
were observed in total with 245 excluding melanomatous skin
SMNs, which was approximately six-fold the number expected.
The cumulative risk of developing an SMN within 25 years of 3-
year survival was 4.2%. This result is comparable with the previous
report on the UK cohort as well as other population-based series.
In the former, a six-fold increased risk was found of SMNs and a
cumulative risk by 25 years from the 3-year survival of 3.7%
(Hawkins et al, 1987). A population-based cohort study of 30880
childhood cancer survivors from the Nordic cancer registries
found 247 SMNs, a SIR of 3.6 and a cumulative risk of SMN by 25
years from diagnosis of 3.5% (Olsen et al, 1993). Similar results
were described in Italy (Magnani et al, 1996). It has previously
Table 3 Risk of SMN after nonretinoblastoma childhood cancer, by duration of follow-up from original diagnosis
Follow-up period from diagnosis (in years)
3–9 10–19 20–29 30 or more
Number entering risk period 15452 7862 2806 808
Person-years accrued during risk period 76594 50685 16695 3189
Observed number of SMNs 92 64 34 11
SIR (O/E) 10.2 5.7 3.5 2.4
95% CI for SIRs 8.3, 12.6 4.4, 7.3 2.4, 4.9 1.2, 4.3
AER per 1000 survivors per year 1.1 1.0 1.5 2.0
SMN¼second malignant neoplasm; O¼observed; E¼expected; SIR¼standardised incidence ratio; AER¼additive excess risk. Statistical test for trend in SIR (unadjusted),
Po0.001. Statistical test for trend in SIR (adjusted), P¼0.002. Statistical test for heterogeneity in SIR (unadjusted), Po0.001. Statistical test for heterogeneity in SIR (adjusted),
P¼0.006.
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cancer diagnosis.
Sites of SMN
Leukaemia Digestive Bone Soft tissue
Breast
(female)
Genital
organs
(female) CNS
Thyroid
and
endocrine
Myeloid
leukaemia
ICD9 code 2040–2089 1400–1599 1700–1709 1710–1719 1740–1749 1790–1849 1910–1929 1930–1949 2050–2059
Duration of
follow up from
the first cancer
diagnosis (in
years)
3–9 O 20 6 20 5 0 1 28 4 15
SIR 10.0 13.4 27.4 13.0 3.2 18.5 14.8 28.9
95% CI 6.1, 15.4 4.9, 29.2 16.7, 42.2 4.2, 30.3 0.1, 17.6 12.3, 26.9 4.0, 37.8 16.2, 47.8
10–19
O29 1 1 86 2 981
SIR 1.9 11.2 23.3 22.6 8.3 1.5 9.4 21.5 2.0
95% CI 0.2, 7.0 11.6, 41.0 5.1, 21.3 9.7, 44.5 3.0, 18.0 0.2, 5.4 4.3, 17.9 9.3, 42.4 0.1, 11.3
2 0 – 2 9 O172 14 5 501
SIR 2.7 6.7 22.0 6.2 2.1 2.9 9.9 4.0
95% CI 0.1, 15.2 2.7, 13.8 2.7, 79.6 0.2, 34.7 0.6, 5.3 1, 6.8 3.2, 23.1 0.1, 22.3
30 or more O 0 5 0 1 1 1 0 1 0
SIR 6.5 21.7 0.8 1.6 16.7
95% CI 2.1, 15.2 0.6, 121.0 0.02, 4.6 0.04, 9.0 0.4, 92.8
Test for
trend
P¼0.1 P¼0.137 P¼0.483 P¼0.978 P¼0.016 P¼0.982 P¼0.017 P¼0.33 P¼0.001
O¼observed; SIR¼standardised incidence ratio; CI¼confidence intervals; CNS¼ central nervous system.
Table 5 SIRs and observed numbers of developing a second malignant neoplasm following all nonretinoblastoma childhood cancers, and selected sites by
treatment received, era of diagnosis and age at diagnosis of the first cancer
Sites of SMN
All SMNs Leuk GI Bone Soft tissue Breast (female) CNS Endocrine Myeloid leuk
Treatment received for primary cancer
Neither RT nor CT 3.3 (26) 1.5 (1) 6.9 (5) 12.8 (3) 0 (0) 0.9 (1) 11.4 (7) 4.7 (1) 3.6 (1)
RT only 6.0 (91) 3.6 (4) 10.4 (17) 31.8 (13) 17.6 (6) 4.2 (9) 13.6 (15) 22.0 (8) 5.8 (3)
CT only 7.4 (12) 11.9 (3) 21.1 (2) 32.0 (3) 16.9 (1) 0 (0) 10.0 (2) 0 (0) 26.1 (2)
Both RT and CT 12.5 (72) 14.6 (15) 9.9 (3) 34.4 (14) 34.5 (8) 6.7 (1) 22.2 (18) 22.2 (4) 38.0 (11)
Test for heterogeneity (unadjusted) Po0.001 Po0.001 P¼0.59 P¼0.45 P¼0.08 P¼0.33 P¼0.29 P¼0.29 Po0.001
Test for heterogeneity (adjusted) P¼0.003 * * * * * * * *
Era of diagnosis
Pre-1970 3.6 (83) 2.0 (3) 6.9 (17) 17.2 (9) 14.8 (7) 2.2 (8) 8.2 (13) 11.0 (6) 2.7 (2)
1970–1979 9.8 (90) 6.5 (9) 12.1 (6) 35.7 (21) 20.1 (7) 10.1 (3) 21.8 (24) 20.2 (6) 11.4 (5)
1980–1987 10.6 (28) 18.5 (11) 35.2 (4) 14.9 (3) 8.1 (1) 0 (0) 10.9 (5) 10.9 (1) 69.9 (10)
Test for trend (unadjusted) Po0.001 Po0.001 P¼0.004 P¼0.61 P¼0.875 P¼0.032 P¼0.132 P¼0.590 Po0.001
Test for heterogeneity (unadjusted) Po0.001 Po0.001 P¼0.005 P¼0.093 P¼0.639 P¼0.045 P¼0.01 P¼0.541 Po0.001
Test for trend (adjusted) P¼0.093 * * * * * * * *
Test for heterogeneity (adjusted) P¼0.10 * * * * * * * *
Age at diagnosis
0–4 7.9 (71) 5.7 (9) 16.3 (9) 26.2 (13) 16.0 (5) 4.2 (2) 17.4 (22) 23.0 (6) 14.1 (6)
5–9 5.8 (54) 3.2 (3) 6.6 (5) 23.6 (10) 14.8 (4) 0 (0) 15.1 (13) 7.8 (2) 5.3 (2)
10–14 4.6 (76) 11.2 (11) 7.4 (13) 25.7 (10) 16.5 (6) 3.6 (9) 6.9 (7) 12.1 (5) 16.9 (9)
Test for trend (unadjusted) P¼0.001 P¼0.14 P¼0.102 P¼0.948 P¼0.954 P¼0.589 P¼0.033 P¼0.296 P¼0.632
Test for heterogeneity (unadjusted) P¼0.005 P¼0.08 P¼0.117 P¼0.967 P¼0.985 P¼0.174 P¼0.084 P¼0.310 P¼0.294
Test for trend (adjusted) P¼0.031 * * * * * * * *
Test for heterogeneity (adjusted) P¼0.09 * * * * * * * *
GI¼digestive; CNS¼central nervous system; Leuk¼leukaemia. *Indicates where numbers were insufficient for multivariate analysis.
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higher risks of SMN than population-based series (Hawkins and
Stevens, 1996). Early hospital-based studies of SMNs after child-
hood cancer, carried out by the Late Effects Study Group (LESG)
reported a SIR of SMN of 15 and a cumulative risk at 20 years from
diagnosis of 12% (Mike et al, 1982; Meadows et al, 1985). However,
the Childhood Cancer Survivor Study, one of the largest and most
comprehensive of treatment-centre-based cohort studies of SMNs,
in the follow-up of 13581 survivors of childhood cancer for a
median of 15 years from the diagnosis of the first cancer, a SIR of
6.38 and a cumulative risk of SMN by 20 years of 3.2% were
reported (Neglia et al, 2001). There is consistency of risk estimates
from the large European population-based series and more recent
hospital-based studies.
The differences in risk estimates between large population-based
and large early hospital-based series may reflect different
therapeutic practices and/or the potential for bias associated with
hospital-based studies, for healthy survivors are more likely to
become lost to follow-up than unhealthy survivors who need to
return for further care, as discussed in detail in relation to large
hospital-based studies of SMNs after childhood Hodgkin’s disease
(Wolden et al, 1998).
After nonretinoblastoma childhood cancers
One of the strengths of this study is the length of follow-up, thus
providing accurate estimates of risks of SMN in successive decades
from diagnosis. We have demonstrated a significant decline in SIR
of SMN with increasing duration of follow-up, which was not
evident in our previous analysis (Hawkins et al, 1987), highest
(10.2) 3 to 9 years after diagnosis with a significant decline in SIR
over subsequent decades. A similar decline in SIR has been
recently reported in another study of survivors of childhood
cancer (de Vathaire et al, 1999), and also in a comprehensive study
of populations irradiated in childhood, including the survivors of
the atomic bombs in Japan (Little et al, 1991). However, perhaps of
particular note for clinicians and the survivors themselves is the
AER by duration of follow-up. The LESG reported a marked rise in
the AER of SMN with duration of follow-up: 1.5 extra cancers per
1000 survivors per year within 2 to 4 years of the first cancer,
which increased to 15 extra cancers after 20 years (Tucker et al,
1984). Although direct comparison is not possible, in our study,
within the first decade from diagnosis of the first cancer, 1.1 extra
cancers were observed per 1000 survivors per year increasing to
only 1.5 extra cancers per 1000 survivors per year beyond 20 years
from diagnosis.
The risk of SMN was influenced by the era of diagnosis of the
first cancer, and our categories (pre-1970, 1970–1979 and 1980
onwards) crudely reflect the change in treatment practice within
British paediatric oncology. Prior to 1970, there was little
chemotherapy used, in the 1970s single-agent chemotherapy and
early treatment protocols were developed and since 1980 there has
been a more widespread use of multiagent chemotherapy. The SIR
rose from 3.6 following treatment in the pre-1970 era to 10.6
among those treated from 1980 onwards, a trend to which digestive
system and breast cancers contributed. Numbers of SMNs in these
groups were small, but there was a highly significant trend
(Po0.001) in the risk of secondary myeloid leukaemia with a
striking increase in the SIR from 2.7 in those treated pre-1970 to
69.9 in the group treated after 1979. All these second primary
myeloid leukaemias were acute, such that the SIRs reported
underestimate the excess risk of such leukaemias. The Nordic
cohort study reported a similar significant trend with a calendar
period of diagnosis for all SMNs, with a trend also in the second
leukaemia group (Olsen et al, 1993). In the present data, the
association between SMN risk and era of diagnosis of the first
cancer was not formally statistically significant in a multivariate
model that included type of treatment for first cancer, suggesting
that this association was due to the confounding effect of the
recent intensive treatment regimes. Acute myeloid leukaemia, the
most frequent of the therapy-related leukaemias, has been
associated with treatment of the first cancer with exposure to
alkylating agents, epipodophyllotoxins and irradiation (Hawkins
et al, 1992; Sandoval et al, 1993). We found substantial
heterogeneity in SIR for SMN in relation to exposure to neither,
either radiotherapy or chemotherapy or both, with the greatest risk
observed in probably the most intensive treatment category (both
chemotherapy and radiotherapy).
Since 1987, treatment protocols have intensified with treatment
given to the limits of patients’ toleration. It is therefore of great
concern that the trend of increasing excess risks of SMN apparent
in our data may be even greater in subsequent decades of
Table 6 Risks of developing an SMN after selected types of first cancer
First cancer diagnosis
Brain and CNS
tumours
Acute
lymphoblastic
leukaemia
Wilm’s
tumour
Hodgkin’s
disease
Soft tissue
tumours Neuroblastoma
Bone
tumours
Number in group 4009 3988 1298 1294 1086 660 638
Person-years
accrued during
study period
43970 24620 15621 12425 12445 7827 5805
Mean follow-up
(years and months)
10y 11m 6y 2m 12y 9y 7m 11y 5m 11y 10m 9y 1m
Observed number
of SMNs
55 17 19 32 14 7 16
SIR (O/E) 4.7 5.3 6.9 9.2 4.3 5.0 8.4
95%CI for SIR 3.6, 6.2 3.1, 8.4 4.2, 10.8 6.3, 13.0 2.3, 7.2 2.0, 10.4 4.8, 13.6
AER per 1000
survivors
1.0 0.6 1.0 2.3 0.86 0.72 2.4
Cumulative risk of
SMN within 20
years of 3-year
survival
2.6%
(s.e.¼0.4%)
2.8%
(s.e.¼0.8%)
2.2%
(s.e.¼0.6%)
1.7%
(s.e.¼0.8%)
SMN¼second malignant neoplasm; O¼observed; SIR¼standardised incidence ratio; CI¼confidence intervals; AER¼additive excess risk; CNS¼central nervous system;
s.e.¼standard error.
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childhood cancer continue to be monitored in order to identify
subgroups at particular risk of SMN. It is important to note,
however, that in comparison with almost certain death from
untreated childhood, the absolute risks of SMN experienced by
survivors are small.
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